Pharmaceuticals

Camzyos Demonstrates Efficacy and Safety in Treating Symptomatic Obstructive Hypertrophic Cardiomyopathy

bexib
By bexib 0 Min Read

Results from the Phase III EXPLORER-LTE trial found that Camzyos maintained efficacy in treating symptomatic obstructive hypertrophic cardiomyopathy after 3.5 years of treatment.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Who will be tomorrow’s world’s richest people? We interviewed teenagers attending the world’s most expensive schools to find out
Next Article Internal and External Page Linking Tips
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Editor’s Pick: Top 3 Features of 2024
Banking
New e-commerce tools: December 26, 2024
Retail & E-commerce
Is it a wise choice to join?
Insurance
Warwickshire’s biggest secret revealed as new speakeasy bar opens
Hospitality & Tourism